A Phase 3, Randomized, Double-masked, Vehicle-controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis

Trial Profile

A Phase 3, Randomized, Double-masked, Vehicle-controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Reproxalap (Primary)
  • Indications Anterior uveitis
  • Focus Therapeutic Use
  • Sponsors Aldeyra Therapeutics
  • Most Recent Events

    • 27 Apr 2017 According to an Aldeyra Therapeutics media release, results from this study are expected in the second half of 2018.
    • 27 Apr 2017 According to an Aldeyra Therapeutics media release, first patient has been enrolled in the study.
    • 27 Apr 2017 Status changed from planning to recruiting, according to an Aldeyra Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top